EHA 2023 Update: There's more to come from EHA... - CLL Support
EHA 2023 Update
You need to be a member of this community to see this post.
2 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis
The meta-analysis of 20 studies on CLL/SLL patients treated with new-generation BTKis was based on...
News about V+O and Acalabrutinib from EHA
Hi,
The future of CLL therapy we believe will include fixed duration treatments of non-chemo drugs....
Early results of the Pirtobrutinib, Obinituzumab, Venetoclax trial I'm on have just been published
Dr. Jain of M.D. Anderson has published an oral abstract in advance of the European Hematological...
Treatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU
The EC approval is based on positive results from two Phase 3 clinical trials: SEQUOIA...
Related Posts
Zanubrutinib looks promising on all fronts in first interim analysis of ALPINE Trial - Ibrutinib v Zanubrutinib in R/R CLL - report from EHA
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom- Acalabrutinib Plus Obinutuzumab Prolongs Progression Free Survival Compared to Other Targeted Agents in Chronic Lymphocytic Leukaemia (CLL)
- Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
- From the CLL14 Study: Venetoclax Plus Obinutuzumab Prolongs Progression Free Survival, Not Overall Survival , in CLL
